Form 4: Omeros Director Dr. Leroy Hood Granted Annual Stock Options

Omeros Corporation's Director, Dr. Leroy E. Hood, was granted 15,000 stock options as part of the company's non-employee director compensation policy, exercisable at $3.2 per share.

Summary

• Dr. Leroy E. Hood, MD PhD, a Director of Omeros Corporation (OMER), was granted 15,000 stock options.
• The transaction date for this grant was June 27, 2025.
• The exercise price for these stock options is $3.2 per share.
• The options have an expiration date of June 27, 2035.
• These options will fully vest and become exercisable on the day before the 2026 annual meeting of Omeros Corporation shareholders, contingent upon Dr. Hood's continued service as a director through that date.
• This grant is an annual stock option award made pursuant to Omeros Corporation's non-employee director compensation policy.

Sentiment

Score: 5

Explanation: The document reports a routine, expected insider transaction related to director compensation, which is neutral in terms of immediate positive or negative sentiment for the company's operational or financial performance.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the value of the options increases with the company's stock price.
• The transaction is part of a pre-established non-employee director compensation policy, indicating a structured approach to executive incentives.

Future Outlook

The vesting schedule of the stock options, contingent on continued service, implies an expectation for Dr. Hood to remain a director through the 2026 annual meeting.

Management Comments

• The annual stock option award granted to the reporting person is in conjunction with the annual meeting of shareholders held on June 27, 2025, pursuant to Omeros Corporation's non-employee director compensation policy.
• The option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors, to attract and retain experienced board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The practice of granting stock options as part of non-employee director compensation is a standard industry practice, comparable to compensation structures seen at other publicly traded biotechnology companies.
• The specific number of options (15,000) and the exercise price ($3.2) are specific to Omeros Corporation's compensation policy and would need comparison with peer companies' director compensation disclosures to assess their competitiveness or typicality within the sector.

Corporate Governance

Related Party Transactions

• The grant of 15,000 stock options to Dr. Leroy E. Hood, a director of Omeros Corporation, constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options could lead to potential future dilution if exercised, but it also aims to align the director's interests with long-term shareholder value creation.
• Directors: Provides a form of equity compensation, incentivizing continued service and performance.

Next Steps

• Dr. Leroy E. Hood's continued service as a director of Omeros Corporation is required for the stock options to fully vest by the day before the 2026 annual meeting of shareholders.

Key Dates

Keywords

Omeros, OMER, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Corporate Governance